Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Boceprevir + PegIFN + Ribavirin in Pediatric CHC GT1
NCT01590225Phase 3Withdrawn
- Sponsor
- Merck & Co.
- Start
- Jan 2013
- Primary completion
- Aug 2021
- Modality
- Orthosteric Ligands
01
Overview
Phase 3, open-label trial of boceprevir in hepatitis C (HCV) (2 arms), sponsored by Merck & Co. Primary endpoints: Sustained Viral Response at Follow-Up Week 24 and Time to Viral Relapse in Study Part C. Planned start Jan 2013; status: withdrawn.
02
Drugs
boceprevir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT01590225.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01590225.